Ketamine for treatment-resistant depression: Recent developments and clinical applications

Evidence-Based Mental Health

Volumn 19, Issue 2, 2016, Pages 35-38

  Schwartz, Jaclyn ^a   Murrough, James W ^a   Iosifescu, Dan V ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; KETAMINE;

DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HUMAN; OUTCOME ASSESSMENT;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HUMANS; KETAMINE; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84963964147     PISSN: 13620347     EISSN: None     Source Type: Journal    
DOI: 10.1136/eb-2016-102355     Document Type: Review

References (35)

1. Marcus M, Yasamy MT van, et al. Depression: a global public health concern. WHO Department of Mental Health and Substance Abuse.
2. Papakostas GI, Ionescu DF. Towards new mechanisms: an update; on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry 2015;10:1142-50.
3. Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 2011;37:851-62.
4. Malhi GS, Byrow Y. Is treatment-resistant depression a useful concept? Evid Based Mental Health 2016;19:1-3.
5. Sanacora G, Zarate CA Jr, Krystal JH, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008;7:426-37.
6. Mathew SJ, Shah A, Lapidus K, et al. Ketamine for treatment-resistant unipolar depression. CNS Drugs 2012;26:189-204.
7. WHO Recommends against international control of ketamine. 2016. http://www.who.int/medicines/access/controlled-substnaces/recommends_against_ick.en/
8. Murrough JW, Iosifescu DV, Chang LC, et al. An antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013;170: 1134-42.
9. Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl) 2014;231:3663-76.
10. McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 2015;45:693-704.
11. Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioral antidepressant responses. Nature 2011;475:91-5.
12. Beurel E, Song L, Jope RS. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 2011;26:1068-70.
13. Kavalali ET, Monteggia LM. How does ketamine elicit a rapid antidepressant response? Curr Opin Pharmacol 2015;20:35-9.
14. Caddy C, Amit BH, McCloud TL, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev 2015;(9): CD011612.
15. DeWilde KE, Levitch CF, Murrough JW, et al. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann NY Acad Sci 2015;1345:47-58.
16. Wan L, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment resistant depression. J Clin Psychiatry 2015;76:247-52.
17. Romeo B, Choucha W, Fossati P, et al. Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Res 2015;23:682-8.
18. Gaynes B. Assessing the risk factors for difficult-to-treat depression and treatment-resistant depression. J Clin Psychiatry 2016;77(Suppl 1):4-8.
19. Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 2014;71:681-8.
20. Murrough JW, Burdick KE, Levitch CF, et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology 2015;40:1084-90.
21. Gorlyn M, Keilp JG, Grunebaum MF, et al. Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. J Neural Transm 2008;115:1213.
22. Monteggia LM, Zarate CA Jr. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol 2015;30:139-43.
23. Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 2014;76:970-6.
24. Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013;74:250-6.
25. Diamond PR, Farmery AD, Atkinson S, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol 2014;28:536-44.
26. Nock MK, Borges G, Bromet EJ, et al. Suicide and suicidal behavior. Epidemiol Rev 2008;30:133-54.
27. Price RB, Mathew SJ. Does ketamine have anti-suicidal properties? Current status and future directions. CNS Drugs 2015;29:181-8.
28. Serafini G, Howland RH, Rovedi F, et al. The role of ketamine in treatment-resistant depression: a systematic review. Curr Neuropharmacol 2014;12:444-6.
29. Larkin GL, Beutrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicidal ideation in the emergency department. Int J Neuropsychopharmacol 2011;14:1127-31.
30. Murrough JW, Soleimani L, DeWilde KE, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med 2015;45:3571-80.
31. Lee Y, Syeda K, Maruschak NA, et al. A new perspective on the anti-suicide effects with ketamine treatment: a procognitive effect. J Clin Psychopharmacol 2016;36:50-6.
32. Lally N, Nugent AC, Luckenbaugh DA, et al. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol 2015;29:596-07.
33. Murrough JW, Collins KA, Fields J, et al. Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. Transl Psychiatry 2015;5:e509.
34. Shi L. The impact of primary care: a focused review. Scientifica 2012;2012:432892.
35. Murrough JW, Wan L, Iacoviello B, et al. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology 2014;231:481-8.